Inhibition of tyrosine kinase receptors by SU6668 promotes abnormal stromal development at the periphery of carcinomas

British Journal of Cancer

Volumn 100, Issue 10, 2009, Pages 1575-1580

  Farace, P ^a   Galie M ^a   Merigo, F ^a   Daducci, A ^a   Calderan, L ^a   Nicolato, E ^a   Degrassi, A ^b   Pesenti, E ^b   Sbarbati, A ^a   Marzola, P ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b NERVIANO MEDICAL SCIENCES   (Italy)

Author keywords

Angiogenesis; Cluster analysis; DCE MRI; HT 29; SU6668; Vascular heterogeneity

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; GADOLINIUM PENTETATE ALBUMIN;

ALGORITHM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER MODEL; CELL STRAIN HT29; COLON CARCINOMA; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DRUG RESPONSE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; MEMBRANE PERMEABILITY; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; TUMOR NECROSIS;

ANIMALS; CARCINOMA; CELL PROLIFERATION; COLONIC NEOPLASMS; DISEASE PROGRESSION; HT29 CELLS; HUMANS; INDOLES; MAGNETIC RESONANCE IMAGING; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; PYRROLES; RECEPTOR PROTEIN-TYROSINE KINASES; STROMAL CELLS; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 67349272041     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605041     Document Type: Article

References (19)

1. Bergers G, Hanahan D (2008) Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8: 592 - 603
2. Bhujwalla ZM, Artemov D, Natarajan K, Ackerstaff E, Solaiyappan M (2001) Vascular differences detected by MRI for metastatic versus nonmeta-static breast and prostate cancer xenografts. Neoplasia 3: 143 - 153
3. Casanovas O, Hicklin DJ, Bergers G, Hanahan D (2005) Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8: 299-309
4. Checkley D, Tessier JJ, Kendrew J, Waterton JC, Wedge SR (2003) Use of dynamic contrast-enhanced MRI to evaluate acute treatment with ZD6474, a VEGF signalling inhibitor, in PC-3 prostate tumours. Br J Cancer 89: 1889-1895
5. Demsar F, Roberts TP, Schwickert HC, Shames DM, van Dijke CF, Mann JS, Saeed M, Brasch RC (1997) A MRI spatial mapping technique for microvascular permeability and tissue blood volume based on macro-molecular contrast agent distribution. Magn Reson Med 37: 236-242
6. Ding C, He X (2004) K-means clustering via principal component analysis. Proceedings of the Twenty-First International Conference on Machine Learning 69: 29
7. Horsman MR, Siemann DW (2006) Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies. Cancer Res 66: 11520-11539
8. Jackson A, O'Connor JP, Parker GJ, Jayson GC (2007) Imaging tumor vascular heterogeneity and angiogenesis using dynamic contrast-enhanced magnetic resonance imaging. Clin Cancer Res 13: 3449-3459
9. Knutson KL, Almand B, Dang Y, Disis ML (2004) Neu antigen-negative variants can be generated after neu-specific antibody therapy in neu transgenic mice. Cancer Res 64: 1146-1151
10. Knutson KL, Lu H, Stone B, Reiman JM, Behrens MD, Prosperi CM, Gad EA, Smorlesi A, Disis ML (2006) Immunoediting of cancers may lead to epithelial to mesenchymal transition. J Immunol 177: 1526-1533
11. Leach MO, Brindle KM, Evelhoch JL, Griffiths JR, Horsman MR, Jackson A, Jayson GC, Judson IR, Knopp MV, Maxwell RJ, Mclntyre D, Padhani AR, Price P, Rathbone R, Rustin GJ, Tofts PS, Tozer GM, Vennart W, Waterton JC, Williams SR, Workman P, Pharmacodynamic/Pharmacokinetic Technologies Advisory Committee, Drug Development Office, Cancer Research UK (2005) The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. Br J Cancer 92: 1599-1610
12. Liotta LA, Kohn EC (2001) The microenvironment of the tumour-host interface. Nature 411: 375-379
13. Marzola P, Degrassi A, Calderan L, Farace P, Crescimanno C, Nicolato E, Giusti A, Pesenti E, Terron A, Sbarbati A, Abrams T, Murray L, Osculati F (2004) In vivo assessment of antiangiogenic activity of SU6668 in an experimental colon carcinoma model. Clin Cancer Res 10: 739-750
14. Moody SE, Perez D, Pan TC, Sarkisian CJ, Portocarrero CP, Sterner CJ, Notorfrancesco KL, Cardiff RD, Chodosh LA (2005) The transcriptional repressor Snail promotes mammary tumor recurrence. Cancer Cell 8: 197-209
15. Mueller MM, Fusenig NE (2004) Friends or foes - bipolar effects of the tumour stroma in cancer. Nat Rev Cancer 4: 839-849
16. O'Connor E, Fieller N, Holmes A, Waterton J (2005) How to analyse dynamic MRI in oncology; advanced histogram analysis gives better statistical power & insight than simple averaging. Proceedings of the International Society of Magnetic Resonance in Medicine 13: 2101
17. O'Connor JP, Jackson A, Parker GJ, Jayson GC (2007) DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents. Br J Cancer 96: 189-195
18. Timke C, Zieher H, Roth A, Hauser K, Lipson KE, Weber KJ, Debus J, Abdollahi A, Huber PE (2008) Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy. Clin Cancer Res 14: 2210-2219
19. Xiong HQ, Herbst R, Faria SC, Scholz C, Davis D, Jackson EF, Madden T, McConkey D, Hicks M, Hess K, Charnsangavej CA, Abbruzzese JL (2004) A phase I surrogate endpoint study of SU6668 in patients with solid tumors. Invest New Drugs 22: 459 - 466